Wankai New Materials Deal History & Licensing Activity
Wankai New Materials is a life sciences. Over the past three years, Wankai New Materials has been involved in 1 licensing and acquisition transaction, with a primary focus on Other (2 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Other
Focus Area
Other
Wankai New Materials Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Wankai New Materials in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| PET depolymerization technology | Carbios | Other | Approved | license | Mar 2026 |
Wankai New Materials Pipeline Focus
Therapeutic areas and modalities where Wankai New Materials is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches Wankai New Materials's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Other assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Wankai New Materials Licensing & Deal Activity
Wankai New Materials is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Wankai New Materials ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Wankai New Materials include Other (2 deals and trials). In terms of modality, Wankai New Materials has shown particular interest in other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Wankai New Materials and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Wankai New Materials's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.